Stock Analiz

Natures Sunshine Products Inc. NATR

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$10.36Market cap $180M
Open the interactive analysis →

Natures Sunshine Products Inc. (NATR) is a healthcare company listed in the US with a market value of about $180M. In the twelve months to September 30, 2026 it had revenue of $480M and net income of $15M, a net margin of 3.1%.

Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is financial health (5/5); the weakest is track record (0/5).

Key numbers: a P/E of 12.6, a price to free cash flow of 17.1, 5-year revenue growth of 4% a year, a 5-year average ROIC of 11%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 8% above the current price.

About Natures Sunshine Products

Natures Sunshine Products is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $366M in 2014 to $480M in 2025, growth of about 2.5% a year. It was profitable in 7 of the last 10 years in our data. Its share count fell by 4% over three years (buybacks). It spends 0% of revenue on research and development.

Score: 2.4 / 5

Value4/5
Future growth1/5
Track record0/5
Financial health5/5
Shareholder returns2/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • Profit margin improving
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Interest covered more than 5 times

Checks not passed

  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)12.6
Forward P/E—
P/FCF17.1
P/S0.4
P/B1.0
EV/EBITDA2.8
PEG—
Dividend yield—
FCF yield5.9%
Shareholder yield9.1%
Intrinsic value vs. price+8%

Growth and quality

Revenue growth (1 yr)5.7%
Revenue growth (5 yrs, per year)4.5%
EPS growth (5 yrs, per year)-0.2%
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)3.1%
ROIC (5-yr avg.)10.6%
Profitable years (of last 10)7
Years paying a dividend3

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$480M$480M$454M$445M$422M$444M$385M$362M$365M$342M$341M
Net income$15M$20M$8M$15M-$390000$29M$21M$7M-$854000-$13M$2M
Free cash flow$11M$29M$14M$31M-$7M$28M$33M$3M$17M$5M-$8M
EPS (diluted)$0.82$1.06$0.40$0.77$-0.02$1.42$1.07$0.34$-0.04$-0.69$0.11
Net margin3.1%4.1%1.7%3.4%-0.1%6.5%5.5%1.9%-0.2%-3.8%0.6%
ROIC—9.4%9.1%8.7%7.7%17.9%9.3%8.2%2.9%0.8%5.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Natures Sunshine Products’s P/E ratio?

About 12.6, based on the last twelve months of diluted earnings per share.

Is Natures Sunshine Products stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 8% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Natures Sunshine Products pay a dividend?

Not currently.

Is Natures Sunshine Products a good stock to buy?

We do not give buy or sell advice. Natures Sunshine Products scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.